PharmaRoth Labs, Inc. Announces Retail and Wholesale Distribution Channels in Mexico
24 3월 2014 - 9:45PM
Marketwired
PharmaRoth Labs, Inc. Announces Retail and Wholesale Distribution
Channels in Mexico
Sucanon(R) Currently Being Sold in Major Outlets Throughout
Mexico
LAS VEGAS, NV--(Marketwired - Mar 24, 2014) - PharmaRoth Labs,
Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH), the exclusive producer,
marketer & distributor of Sucanon®, an oral Type-II Diabetes
treatment, announced today the retail and wholesale distribution
channels for sales of their proprietary drug in Mexico. These
distributors have come through the Company's exclusive marketing
partner, Marcas de Renombre (MDR). Sucanon® is being sold retail in
Walmart, Farmacias Benavides, Farmacias del Ahorro and HEB. The
wholesale distributor that supplies smaller retailers is NADRO.
MDR is also utilizing extensive media advertising for Sucanon®
in Mexico to drive sales of the drug. Mexican networks TV Azteca
and Televisa are broadcasting 20 and 60 seconds ads on their
national channels several times per day. The advertising was
created by MDR in conjunction with PharmaRoth, and was approved by
the Mexican Health Authority. In conjunction with the television
advertising, MDR has successfully placed product banners in Mexico
City's largest soccer stadium, making Sucanon® visible to thousands
of fans, both live and during on-air television coverage of
events.
"We are very excited to announce the retail and wholesale
distributors that our exclusive partner, MDR, has placed our
product in," commented Luis Lopez, CEO of PharmaRoth. "The
combination of placing Sucanon® in major Mexican sales outlets and
the extensive advertising on the national networks have generated
enormous attention for the product. The direct link between our
relationship MDR and the increase in sales demonstrates the value
of having the right partner in our target market," Mr. Lopez went
on to say.
For further information regarding Sucanon®, please visit
PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth
PharmaRoth Labs, Inc. (OTC Pink: ROTH) (PINKSHEETS: ROTH) is
focused on diabetes prevention and treatments. The Company holds
the intellectual property and all exclusive world-wide rights
related to the production, marketing, and distribution of Sucanon®,
an oral treatment for Type-II diabetes. Sucanon® is a member of a
class of diabetic medications called insulin sensitizers. Insulin
sensitizers lower blood sugar by increasing the muscle, fat and
liver's sensitivity to insulin. Insulin sensitizers are blood sugar
normalizing or euglycemic drugs that help return the blood sugar to
the normal range without the risk of low blood sugars. PharmaRoth's
strategy is to increase awareness, acceptance, and distribution of
Sucanon® globally.
For further information regarding Sucanon®, please visit
PharmaRoth Labs, Inc. website at www.pharmaroth.com
Forward Looking Statements: Statements in this document contain
certain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, as amended. These statements are based on
many assumptions and estimates and are not guarantees of future
performance. These statements may involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of PharmaRoth Labs, Inc. to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. PharmaRoth Labs, Inc. assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Our actual
results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors. There may
be other factors not mentioned above that may cause actual results
to differ materially from those projected in any forward-looking
statement. We assume no obligation to update any
forward-looking statements as a result of new information, future
events or developments, except as required by applicable securities
laws.
For Investor Relations contact: Michael Irving Paramount
Advisors, LLC (407) 878-5462
PharmaRoth Labs (CE) (USOTC:ROTH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
PharmaRoth Labs (CE) (USOTC:ROTH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024